Загрузка...
In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide
Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfu...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3957899/ https://ncbi.nlm.nih.gov/pubmed/24366751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02440-13 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|